RenovoRx (RNXT) Other Non-Current Liabilities (2020)
RenovoRx (RNXT) posted Other Non-Current Liabilities of $856000.0 for Q4 2020.
RenovoRx (RNXT) Other Non-Current Liabilities (2020) Analysis & Trends
RenovoRx has reported Other Non-Current Liabilities for 1 years, with the latest figure at $856000.0 in Q4 2020.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $856000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $856000.0 (changed N/A YoY) and the FY2020 annual result came in at $856000.0, changed N/A from the prior year.
- Other Non-Current Liabilities steadied at $856000.0 in Q4 2020 per RNXT's latest filing.
- Over five years, Other Non-Current Liabilities peaked at $856000.0 in Q4 2020 and troughed at $856000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | RenovoRx | 62.43 Mn | 62.43 Mn | 766,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 856,000.00 |